Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies

E-ISSN： 1532-6535|97|5|455-468

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.5, 2015-05, pp. : 455-468

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 5, 2015-05 ,pp. : 469-477

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targets for Ibrutinib Beyond B Cell Malignancies

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (ELECTRONIC), Vol. 82, Iss. 3, 2015-09 ,pp. : 208-217

John Wiley & Sons Inc

Access to resources Recommend Favorite

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 3, 2018-02 ,pp. : 429-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3424-3435

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 683-688

John Wiley & Sons Inc

Access to resources Recommend Favorite